Navigation Links
Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
Date:3/15/2012

DUBLIN, March 15, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

  • A strategic step in building Shire's hematology business (which already includes Xagrid and a growing development pipeline)
  • Adds a differentiated product in development (iron chelator FBS0701), with global rights, in a global market currently worth over $900 million and growing(1)
  • Serves chronic patient need for treatment of iron overload following numerous blood transfusions.  Excess iron in vital organs such as the liver and heart increases the risk of organ failure and is the principal cause of death in transfusion-dependent patients(2)
  • Consistent with Shire strategy of developing and commercializing differentiated specialist products prescribed by specialist physicians (hematologists/ hematologist-oncologists) served by a small sales force
  • FBS0701 will be developed to demonstrate clinical efficacy and an attractive safety profile relative to currently approved chelating agents:
  • Global filing planned for indications for Myelodysplastic Syndrome and hemoglobinopathies initially
  • Phase 2 studies underway with additional trials planned

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
    2. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
    3. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
    4. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
    5. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
    6. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
    7. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
    8. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
    9. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
    10. Reportlinker Adds Shire plc: PharmaVitae Profile
    11. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
    (Date:12/24/2014)... 2014 According to Ross Selinger, President of ... ITRA Global, the national office market continues to be strong, ... is evidenced by the third quarter’s surprising 3.9% GDP, unemployment ... energy costs have held inflation down and the Fed is ... housing market remaining soft. , This solid economic news is ...
    (Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
    (Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
    Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
    ... SAN FRANCISCO, Calif., Sept. 7 Monogram,Biosciences, Inc. (Nasdaq: ... CEO,and Chairman, is scheduled to present a corporate overview ... September 17,2007 at 1:30 p.m. Eastern Time (10:30 a.m. ... California. To access the live audio broadcast or ...
    ... Thursday, October,18, 2007, Wyeth (NYSE: WYE ) will ... will hold a one-hour conference call with,research analysts at ... and others may listen to the call live or ... be accessed by visiting our website,at http://www.wyeth.com ...
    ... Identify microRNA Biomarkers for Overall Survival and Risk ... of Melanoma Metastasizing to Distant Sites, REHOVOT, ... ROSG ), a global leader in the field of,microRNA ... with,NYU Medical Center to leverage the significant potential of microRNA,profiles ...
    Cached Biology Technology:Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5
    (Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
    (Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... reason about the natural world? How do they understand ... decades, the consensus was that as young children begin ... stance, favoring humans over non-human animals when it comes ... Northwestern University researchers have taken another look at the ...
    ... Research Fellow at the Department of Medicine, University of Auckland ... and Outcomes Research at Amaris, UK, have been announced as ... The award, an honorarium of 2,000 Euros each, was ... (first authors under the age of 40) that were submitted ...
    ... Hinxton, 10 May 2010 The European Nucleotide Archive ... to become Europe,s primary access point to globally comprehensive ... available from the European Bioinformatics Institute (EMBL-EBI), a part ... DNA sequencing has led to previously unimaginable amounts of ...
    Cached Biology News:Animals talk, sing and act like humans? 2Enabling easy access to DNA sequence information 2
    ...
    Reacts with the 80 kDa fragment of the M-chain of human merosin....
    Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
    ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
    Biology Products: